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Purpose: To assess the incidence of thyroid malignancy in
an adult population screened by high-resolution ultrasono-
graphy at a medical screening center and to compare the
clinical and pathological features of screen-detected thyroid
carcinomas to symptomatic overt thyroid carcinomas. Materials
and Methods: We calculated the prevalence of screen-detected
thyroid cancer at a medical screening center using high-
resolution ultrasonography and fine needle aspiration. We then
compared the clinical and pathological features of screen-
detected thyroid cancers (n = 46) to clinical symptomatic
thyroid cancers (n = 157). We evaluated age, gender, size,
perithyroidal extension, lymphovascular extension, stage,
histological lymph node metastasis, and the type of cancer. We
also compared the above findings of micropapillary carcinomas
to papillary thyroid carcinomas that were larger than 1 cm in
diameter. Results: Screen-detected thyroid nodule patients
were 2,747 (37%) of 7,491 patients. Nodules selected for fine
needle aspiration were 658 and cytology confirmed malignancy
were 79 (12%) nodules. When screen-detected thyroid cancers
(n = 46) were compared to symptomatic overt thyroid cancers
(n = 157), only statistically significant factor was size (p =
0.002). Papillary thyroid carcinomas that were larger than 1
cm had more frequent capsular invasion (p = 0.000) and a
higher stage (p = 0.027), and a higher prevalence of lymph
node metastases (p = 0.002). Conclusion: Screen-detected
thyroid cancers should be managed as same as symptomatic
thyroid cancers in respect to size, and an assessment should
strictly be based on the ultrasound features and fine needle
aspiration biopsy findings.
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INTRODUCTION
The widespread use of high resolution sono-
graphy (HRS)
1 as a screening tool for thyroid
cancer in medical health care in Korea is
increasing,
2 and its use has generated a number
of issues. There is very limited evidence of the use
of the modality to be cost effective.
3 Furthermore,
the management of thyroid nodules detected
during screening with HRS remains controversial.
Performing screening HRS for thyroid cancer can
lead to the identification of a large number of
small benign-appearing nodules and can lead to
unnecessary studies thus increasing the cost of
health care.
3,4 However, the demand for screening
HRS by the self-referred patient is on the increase,
and the medical faculty does not currently
intervene in the decision of patients to undergo
screening. The rate of thyroid cancer for screen-
detected thyroid nodules at medical centers in
Korea is increasing due to better performance of
fine-needle aspiration biopsy (FNAB) and ultra-
sound (US).
5-8 The incidence of thyroid cancer for
screening thyroid US has been reported in limited
studies,
9 and previous reports were mainly based
on the finding of autopsy cases with a wide range
of malignancy rates of 5 - 35%.
10-12 We investigated
the actual prevalence of thyroid cancer in a
voluntary cancer-screening program in healthy
subjects without a previous history of malignancy
to evaluate the value of ultrasound for screening
thyroid cancer.
As previously reported, many autopsy studies
have suggested that most occult thyroid
carcinomas follow a relatively benign or indolent
course,
12,13 and there has been a recognition of
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different biological behavior between the really
"occult" and clinically overt cancers.
1,14 We,
therefore, compared the clinical and pathological
features of screen-detected thyroid cancers to
symptomatic cancers to evaluate if a different
approach of management is necessary.
MATERIALS AND METHODS
Patient selection
From March 2006 to February 2008, 7,491
consecutive subjects underwent screening thyroid
HRS at a medical health care center, Kangbuk
Samsung Hospital, in the Republic of Korea.
Informed consent was waived for all patients who
underwent thyroid US and FNAB. Approximately
37% of patients (n = 2,747) had a thyroid nodule
or nodules. Among these subjects, 658 patients
(24%) underwent fine needle aspiration for having
a solid nodule larger than 1 cm or a nodule less
than 1 cm, however, showed at least one malignant
US feature. Seventy-nine patients (12%) had a
cytology result of being positive for a malignancy
and 46 patients underwent a surgical procedure at
our hospital (Fig. 1).
During the same period, 287 referred patients
underwent the FNAB procedure at the Depart-
ment of Radiology, and 254 patients underwent a
surgical procedure. Patients (n = 157) who had at
least 1 of the following symptoms or had over-
lapping symptoms, including a palpable neck
lesion (n = 89), voice change (n = 21), swallowing
difficulty (n = 6) and neck pain (n = 54), were in-
cluded as representing patients with symptomatic
thyroid cancer. When there was more than one
cancer nodule confirmed, the largest major lesion
was considered for evaluation, whereas ipsilateral
smaller lesions were disregarded for the patholo-
gical analysis. For statistical purposes of com-
parison, bilateral symptomatic thyroid cancer (n =
2) cases were excluded from the study.
Fig. 1. Flow chart of patients undergoing high resolution ultrasound at a medical center for thyroid
cancer screening. US, ultrasound; F/U, follow up.Yoon Jung Choi, et al.
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US imaging
We used an HDI 5000 (Advanced Technology
Laboratories, Bothell, WA, USA), IU22 (Philips
Medical Systems, Bothell, WA, USA), or LOGIQ
700 ultrasound scanner (GE Medical Systems,
Milwaukee, WI, USA) equipped with a 5 - 12 MHz
linear-array transducer. Board-certified radio-
logists with at least 5 years of experience in
thyroid US performed all of the sonographic
examinations.
Indications for US guided FNAB for nodules
that were larger than 1 cm were based primarily
on the internal content of the lesions. A pre-
dominantly cystic nodule (cyst portion more than
50%) and nodules with an internal spongiform
appearance were not candidates for FNAB.
15
Candidates for FNAB for nodules less than 1 cm
on the longest diameter on a longitudinal scan
were nodules with at least 1 finding of microcalci-
fications, an irregular shape, an ill defined margin
and a solid nodule with echogenicity that was
lower than the echogenicity of strap muscle.
16
Three board certified radiologists performed
US-FNAB using a 23-gauge needle attached to a
10 cc syringe with an aspirator. Movement of the
needle tip toward and into the target was
visualized by real time-US. Based on a cytological
evaluation, nodules were classified as malignant,
indeterminant, benign, or an inadequate sample.
A positive malignant cell based on an FNAB
cytology finding was considered as a screen-
detected thyroid cancer.
We compared 46 screen-detected thyroid cancers
to 157 symptomatic thyroid cancers to determine
if there were any existing differences in age,
gender, size of the cancer, peri-thyroidal exten-
sion, lympho-vascular invasion, underlying
pathology, stage, and lymph node invasion status
and pathological type. The underlying pathologies
were evaluated and compared to clinically overt
tumors. We also compared the above-mentioned
features of micropapillary carcinomas (MPCs) (n
= 111) to papillary thyroid carcinomas (PTCs) (n
= 92) to evaluate different findings.
Statistical analysis was performed by use of
chi-squared test or Fisher's exact test to compare
categorical variables, and by Student's t-test to
compare continuous variables between groups
using SPSS version 10.0 (Chicago, IL USA). Pro-
bability levels less than 0.05 were considered as
statistically significant.
RESULTS
Thyroid HRS performed as screening for thyroid
cancer
For two consecutive years, 7,491 subjects under-
went screening of thyroid HRS. Among the subjects
screened, 2,477 (33%) participants had a normal
thyroid and 1,626 participants (21.7%) presented
with a colloid cyst. Approximately 76 subjects
(1%) had lesions that were suspicious for diffuse
thyroid infiltrative disease with heterogenous
coarse mixed parenchymal echogenicity with
nodular enlargement, and 547 subjects (6.9%)
were diagnosed with a US feature that was
suspicious of thyroiditis. There were 2,747 subjects
(36.7%) with thyroid nodules. Fig. 1 demonstrates
the flow chart of nodule evaluation. Among
subjects that had a thyroid nodule or nodules (n
= 2,747), 658 patients (23.95%) underwent FNAB
for presenting with a solid nodule larger than 1
cm or a nodule less than 1 cm, however, showed
at least one US feature suggestive of a malign-
ancy. Table 1 shows the cytology results of FNAB
for the screened patients, symptomatic patients
and nodules according to sizes. Of the subjects
screened, 461 subjects (70.0%) were negative for a
malignancy, based on a cytology finding, 79
subjects (12.0%) were positive for a malignancy,
22 (3.3%) subjects had an indeterminate cytology,
and 96 subjects (14.6%) had an inadequate cellular
sample for diagnosis. In symptomatic referred
patients, malignant cell cytology was identified in
59.2% of patients. When categorized according to
size, 24.9% of inadequate specimens consisted of
a nodule less than 1 cm in size and only 1.5% of
inadequate specimens consisted of nodules larger
than 1 cm. Table 2 depicts the cytology results of
46 patients whose nodules were identified by
screening US at the medical screening center.
Having an underlying pathology did not influence
the preoperative diagnostic rate by FNAB for
screen-identified cancers and clinical overt thyroid
cancers (p = 0.811).Prevalence and Characters of Screen-found Thyroid Cancer
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Comparison of clinically overt and occult PMCs
Table 3 summarizes and compares the clinico-
pathological features of patients with screen-
detected cancers and symptomatic thyroid cancers.
The size of symptomatic cancers was significantly
larger than the screen-detected tumors (1.141 ±
0.796 cm versus 0.852 ± 0.439 cm; p = 0.002) and
was statistically significant. Out of 46 (65%)
surgically confirmed screen-identified cancers, 30
cancers were identified as microcarcinomas.
Thyroid cancers were found more frequently in
women in screened subjects as well as sympto-
matic subjects (p = 0.339), and age was not a
statistically significant factor. Differences in extra-
thyroidal extension (34.8% vs. 40.8%), vascular
invasion (8.7% vs. 4.5%), and cervical lymph
node invasion (28.3% versus 29.9%) were not
statistically significant between the screened
subjects and symptomatic subjects (p < 0.005). Of
46 patients with occult tumors, 19 patients (41.3%)
were in stage 3, and they underwent a bilateral
thyroidectomy and central neck node dissection
with lateral lymph node dissection, whereas 59 of
157 patients (37.6%) with clinically overt PTCs
were diagnosed as stage 3 and received a
bilateral thyroidectomy (p = 0.808). The histologi-
cal type was mainly well-differentiated type
papillary carcinomas in both screened subjects as
well as in the symptomatic subjects. For screen-
identified cancers, 93.5% of the cancers were
papillary, 2 cancers were Hurthle cell carcinomas
and 1 patient was diagnosed with a follicular
carcinoma. For the symptomatic patients, 97.5%
were identified with papillary cancers and 4
patients had a follicular carcinoma.
Comparison of PMCs and PTCs
When PMCs and PTCs were compared and
analyzed (Table 4), extrathyoidal extension (25.2%
versus 56.5%), vascular invasion (0.9% versus
7.6%), lymphatic invasion (1.8% vs. 9.8%) and
cervical lymph node invasion (20.7% vs. 40.2%)
occurred more frequently in papillary carcinomas
larger than 1 cm in the longest diameter and with
a higher stage (stage 3, 31.5% vs. 46.7%). These
findings were statistically significant (p < 0.005).
Table 1. Fine-needle Aspiration Results in Screen-identified Nodules and Clinically Overt Nodules
FNAB cytology
result
Nodules identified by
screening US
(n = 658)
Clinical overt thyroid
nodules
(n = 287)
Nodules less
than 1 cm
(n = 189)
Nodules larger than
1 cm
(n = 756)
Benign, n (%) 461 (70.0%) 56 (19.5%) 24 (12.7%) 553 (73.1%)
Malignant, n (%) 79 (12.0%) 170 (59.2%) 93 (49.2%) 88 (11.6%)
Indeterminate, n (%) 22 (3.3%) 30 (10.5%) 25 (13.2%) 104 (13.8%)
Inadequate, n (%) 96 (14.6%) 31 (10.8%) 47 (24.9%) 11 (1.5%)
FNAB, fine-needle aspiration biopsy; US, ultrasound.
Table 2. Surgically Confirmed Thyroid Malignant Nodules on Screening Ultrasound at a Medical Screening Center
US impression
Fine-needle aspiration cytology result Pathology
Benign Indeterminate Malignant
Follicular
carcinoma
Hurthle cell
carcinoma
Papillary
carcinoma
Benign (n = 3) 0 0 3 0 0 0
Borderline (n = 8) 1 2 5 1 2 0
Malignant (n = 35) 1 3 31 0 0 43
Total (n = 46) 2 5 39 1 2 43
US, ultrasound.Yoon Jung Choi, et al.
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DISCUSSION
Rate of malignancy in thyroid nodules detected at
a medical screening center
Thyroid nodules are found by palpation in 4 -
8% of the general population in adults,
17 and are
more frequently detected at a rate of 30 - 50% on
sonography
9,18,19 and 50% in autopsy cases.
20 The
malignancy rate has been reported at 7 - 15%;
8,21
the malignancy rate within thyroid inciden-
talomas was 12 - 28.8%.
6,8 The malignancy rate is
increasing due to wide use of highly sensitive US
for routine health examinations.
22 The rate of
thyroid incidentalomas at our institute was
36.67%, with a malignancy rate of 12%. The
malignancy rates for thyroid incidentaloma,
however, differ among institutes, and this differ-
ence may be due to a selection bias of candidates
selected for FNAB that is different among various
institutes. In our institution, solid nodules larger
than 1 cm are considered as candidates for FNAB.
Nodules less than 1 cm in the longest diameter
with at least 1 US feature of suspicious malignant
finding are also considered as candidates for
FNAB. When nodules are depicted as purely
cystic nodules, nodules are not considered as
candidates for FNAB, regardless of size. There are
no US characteristics of a nodule that can be used
to prove that a nodule is benign 4. If FNABs are
performed in all patients who had nodules despite
the US features, incidence of malignancies in the
screening population would better be depicted.
However, performance of extraneous FNABs
increases the cost of health care. There are US
features of thyroid malignancies that distinguish
nodules from benign nodules to suspicious of
malignancy nodules, but some of the features
overlap. Further studies are needed to obtain a
consensus of FNAB indications for screen-detected
Table 3. Patients and Pathological Features of Thyroid Cancer
Characteristics Screening C (n = 46) Symptomatic Ca (n = 157) p value
Patient characteristics
Age (yrs) 51.13 ± 11.56 48.15 ± 11.24 0.118
Sex Female 39/46 (84.8%)
7/46 (15.2%)
123/157 (78.3%)
25/157 (21.7%)
0.339
Male
Pathological finding
Size 0.599 ± 0.154 1.650 ± 0.758 0.000
Rate of micro PTC 29 (63%) 54 (34.4%) 0.000
Capsule invasion 16/46 (34.8%) 64/157 (40.8%) 0.465
Lymphatic invasion 4/46 (8.7%) 7/157 (4.5%) 0.274
Blood vessel invasion 1/46 (2.2%) 7/157 (4.5%) 0.686
Underlying pathology 14/46 (33.3%) 46/157 (29.3%) 0.561
Stage 1. 27/46 (58.7%)
2. 0 (0%)
3. 19/46 (41.3%)
1. 95/157 (60.5%)
2. 3/157 (1.9%)
3. 59/157 (37.6%)
0.808
Histology type Papillary 43/46 (93.5%)
Hurthle cell 2 (4.3%)
Follicular 1/46 (2.2%)
Papillary 153/157 (97.5%)
Follicular 4/157 (2.5%)
0.811
LN invasion 13/46 (28.3%) 47/157 (29.9%) 0.827
LN, lymph nodes; PTC, papillary thyroid carcinoma; C, indicates screen detected cancer; Ca, cancer.Prevalence and Characters of Screen-found Thyroid Cancer
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nodules and US features of benign nodules with
high diagnostic accuracy to preclude the under-
taking of an FNAB. The rate of malignancy based
on the cytology results is higher in nodules less
than 1 cm (49.2% vs. 11.6%) because of the FNAB
indications employed.
Wide use of screening thyroid US at medical
centers in Korea to detect thyroid cancer is
difficult because of limited evidence of cost
effectiveness along with controversies remaining
in management of the disease. However, screening
with FNAB detects early cancers that present with
a smaller size, and patients can undergo treatment
at an earlier stage to reduce possible morbidity
and mortality. In addition, screen-detected cancers
do not behave like "occult" or indolent cancers,
but the pathological characteristics are more
similar to the characteristics of symptomatic clinical
overt cancers, indicating that there are benefits of
screening thyroid US. When a self-referred patient
demands screening HRS, there is no reason to
counter the demand or decision to undertake
HRS, because of high malignancy rate observed
with screen-detected thyroid nodules and early
detection of smaller sized cancers.
Differences between screen-detected cancers and
symptomatic thyroid cancers
The gender distribution of thyroid cancers was
not different between subjects with screen-detected
and clinically overt thyroid cancers. More females
than males presented with cancers, as has been
reported previously.
6,23 Age is an important
prognostic factor relative to mortality in thyroid
cancer. In our study, however no statistical age
differences existed between screen-detected
thyroid cancers and clinically overt cancers. Age
as a risk factor should be evaluated with a
prospective study of thyroid cancer prognosis, but
Table 4. Patient and Pathological Features of Papillary Microcarcinomas (Longest Diameter < 1 cm) and Papillary
Thyroid Carcinomas (> 1 cm)
Characteristics
Microcarcinoma (PMC)
(n = 111)
Papillary thyroid carcinoma
(PTC > 1 cm) (n = 157)
p value
Patient characteristics
Age (yrs) 48.46 ± 10.49 49.27 ± 12.36 0.613
Sex Female 88/111 (79.3%)
23/111 (20.7%)
74/92 (80.4%)
18/92 (19.6%)
0.838
Male
Pathological finding
Size 0.599 ± 0.1540 1.650 ± 0.758 0.000
Capsule invasion 28/111 (25.2%) 52/92 (56.5%) 0.000
Lymphatic invasion 2/111 (1.8%) 9/92 (9.8%) 0.025
Blood vessel invasion 1/111 (0.9%) 7/92 (7.6%) 0.024
Underlying pathology 41/111 (36.9%) 35/92 (38.0%) 0.871
Stage 1. 76/111 (75.5%)
2. 0 (0%)
3. 35/111 (31.5%)
1. 46/92 (50.0%)
2. 3/92 (3.3%)
3. 43/92 (46.7%)
0.016
Histology type Papillary 111/111(100%) Papillary 85/92 (92.4%)
Hurthle cell 2
Follicular 5/92 (5.5%)
0.006
LN invasion 23/111 (20.7%) 37/92 (40.2%) 0.002
LN, lymph nodes; PTC, papillary thyroid carcinoma; PMC, papillary microcarcinoma.Yoon Jung Choi, et al.
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not with a cross sectional study. Most screen-
detected thyroid cancers were well-differentiated
thyroid cancers, and no difference in the rate was
seen between screen-detected cancers and
symptomatic thyroid cancers. This may be a
reason for a stable mortality despite the increasing
prevalence of thyroid cancer.
24
Approximately 65% of surgically confirmed
screen found cancers were microcarcinomas, a
cancer measuring less than 1 cm in the longest
diameter.
25 The management of microcarcinomas
is still controversial. An observational trial of
papillary microcarcinomas in 162 patient without
surgical procedures by Ito et al in Japan
26 showed
that more than 70% of tumors either did not
change or decreased in size, or enlarged by more
than 10 mm in 10.2% of cases; lymph node
metastasis in the lateral compartments appeared
in only 1.2% of patients during follow-up. In
addition, a metastasis was confirmed histologically
in 50.5% of cases and multiple tumor formation
was seen in 42.8% of patients with a rate of
recurrence of 2.7% at 5 years and 5.0% at 8 years
after surgery. Investigators suggested that
papillary microcarcinomas frequently did not
become clinically apparent, therefore, patients can
wait while tumors are not progressing, although
lesions are pathologically multifocal and involve
lymph nodes at an high incidence. According to
our present data, performing screening thyroid
US can lead to excessive and unnecessary surgical
procedures. We cannot differentiate which nodule
progresses aggressively and which nodule stays
indolent or occult. Biological behavior of micro-
carcinomas is currently not clear. Many published
studies described an aggressive clinical course of
micropapillary carcinomas, showing high lymph
node invasion, therefore, there would be a very
limited number of patients who would choose
follow-up rather than a surgical procedure if a
treatment option is given. In a study of prognostic
factors and extension of thyroid microcarcinomas
in Korean patients, about 29.0% of patients
presented with lymph node metastasis and
extrathyroidal extension.
27 Similar findings were
also found in the present study, with 28/111
patients (25.2%) presented with capsule invasion
and 23/111 patients (20.7%) presented with lymph
node invasion. Thyroid microcarcinomas in
Korean patients may be associated with poor
prognostic factors, and appears to exist at relatively
higher cancer stages but with a relatively low
mortality rate. Therefore, the value of thyroid
cancer screening should further be studied and
management of micropapillary carcinomas should
further be investigated, because most cancers
found at screening centers appeared to be micro-
carcinomas.
When comparing the histopathology features in
the screened-subjects and symptomatic subjects,
clinically overt thyroid cancers presented with a
larger size, whereas, the other clinical and patho-
logical features were not statistically different,
thus suggesting that screen found thyroid cancer
and clinically overt symptomatic thyroid cancer
should equally be treated. Kasai et al. reported
that occult thyroid cancer follows a rather benign
clinical course, suggesting a less aggressive
treatment, however, also found that lymph node
metastasis and extrathyroidal extension increase
as the size of malignant nodules increase,
28 which
is concordant with our present results (Table 4).
Earlier diagnosis with proper surgical removal of
the tumor before distant metastasis may help
improve prognosis of thyroid cancer patients.
Radiological or cytological evaluation cannot
determine cancer behavior, and it is standard
practice in Korea to perform a thyroidectomy once
a thyroid carcinoma is identified. Therefore,
further prospective study on the natural history of
occult thyroid carcinomas is needed. We attempted
to identify any different clinical and pathological
features between the screen-identified cancers and
symptomatic cancers to provide evidence to
justify less aggressive treatment, however, our
results showed no statistical significant difference.
Our findings support that screen-detected thyroid
malignancies require investigation and treatment
similar to those of clinically overt thyroid cancers.
Since HRS detects too many small, non-palpable
thyroid nodules which are mostly benign, a
simple follow-up neck palpation has been
suggested to be sufficient,
29 however, we strongly
believe that it should strictly be evaluated based
on US characteristics and FNAB cytology findings
once an incidentaloma is identified.
The primary limitation of this study is that the
prevalence of thyroid nodules and cancer is basedPrevalence and Characters of Screen-found Thyroid Cancer
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on a population that requested thyroid screening
ultrasound. The medical faculty did not interfere
in a decision of a patient, however, this particular
population of subjects may not represent a general
population, because of specific age and economic
status differences of patients that seek health care.
Second, FNAB was not performed on every single
nodule found at the medical screening center, but
was performed mainly based on the presence of
specific US features. No definite US feature for a
benign nodule exists. Consequently the FNAB
indication used can generate false negative cases,
providing a selection bias. A further investigation
is needed to evaluate the value of screening
thyroid US and strict FNAB guidelines for screen-
identified nodules. Third, this study is a retrospec-
tive study. We hypothesized that screen-identified
cancers behave in a manner similar to clinically
occult thyroid cancers, however, which cancer
stays occult while which cancer manifests as overt
disease is not known.
Although many investigators have extensively
described the approach to treatment of palpable
or symptomatic thyroid nodules,
20,30-32 there still
remains disagreement about the accepted evalua-
tion and treatment of incidental thyroid nodules.
33,34
We think that the current system of wide use of
screening for thyroid cancer is difficult to justify
with such limited evidence of cost effectiveness of
screening and the controversies still remaining for
the management of thyroid incidentalomas and
microcarcinomas. However, when a self-referred
patient demands screening HRS, there is no
reason to interfere with the demand or decision to
undergo HRS. Thus, if the medical center
performs screening thyroid ultrasound, nodules
found in a screening setting should strictly be
managed, based on US characteristics and FNAB
cytology findings, and screen-identified cancers
should be treated in the same way as clinically
symptomatic thyroid nodules.
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